The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications Authors: Qian Gao, George Fu Gao, Jun Liu Published: 2026 ABSTRACT Highlights•Priority Pathogens are the recognized pathogens anticipated to pose a significant public health threat.•The protective immunogens of pathogens act as targets of new-type vaccines and drugs.•Viruses within the same family generally possess homologous protective immunogens.•Conserved internal viral proteins serve as promising candidates for developing universal vaccines. Introduction Historically, risky pathogens have sparked numerous epidemics of infectious diseases and caused enormous losses. The severe disruptions to healthcare systems and social orders triggered by sudden infectious disease outbreaks highlight the importance of preparedness. Although the coronavirus disease 2019 (COVID-19) pandemic seems to be alleviating, more preventive countermeasures should be taken to prepare for the inevitable next pandemic. In 2024, the World Health Organization (WHO) published a report focusing on the evaluation of the danger of various global epidemic pathogens and the updating of Priority Pathogens in terms of the assessed public health risks [1]. In this document, the WHO proposed the 32 Priority Pathogens which could cause a Public Health Emergency of International Concern (PHEIC) or a pandemic according to the patterns of transmission, virulence, and access to countermeasures. Identifying Priority Pathogens enables the rational allocation of limited public health resources to the pathogens most likely to trigger severe outbreaks. Protective immunogens are core candidates for vaccine and therapeutic development targeting Priority Pathogens as they can stimulate host immune responses and exert protective effects. In this review, we listed the representative protective immunogens of each Priority Pathogen and summarized their characteristics. Viruses within the same taxonomic family generally possess homologous protective immunogens. Some cross-reactive protective immunogens, which are more common in viruses within the same family, and relatively conserved internal viral proteins, serve as promising targets for universal vaccine development. Furthermore, we outlined recent advances, existing challenges, and future prospects regarding the application of protective immunogens for Priority Pathogens. Priority Pathogens The Priority Pathogens refer to the pathogens that can cause a PHEIC or a pandemic. The International Committee on Taxonomy of Viruses (ICTV) helped create an initial list of viral families containing pathogens that can infect humans and have the potential to cause outbreaks. Soon afterwards, over 200 scientists from 54 countries evaluated the evidence related to these 28 viral families and one core group of bacteria, encompassing 1,652 pathogens, according to the existing knowledge of patterns of transmission, virulence and access to countermeasures. The Priority Pathogens List for 2024 presented a new understanding of pathogens and an updated assessment of global health threats. Compared with the Priority Pathogens List published by the WHO in 2017 and 2018, more than 20 “new” Priority Pathogens were added [1]. After the update, the number of Priority Pathogens exceeds 30 and includes many emerging and re-emerging pathogens such as the virus causing COVID-19, mpox, and dengue fever. Of note, the Priority Pathogen can be either a species of virus or a subgenus of virus, such as subgenus Sarbecovirus, which includes severe acute respiratory syndrome coronavirus (SARS-CoV). The Priority Pathogens List for 2024 consists of 27 viruses and five bacteria [1]. According to syndromes or transmission routes, the viruses in the Priority Pathogens List are largely classified as respiratory viruses [Subgenus Sarbecovirus, Subgenus Merbecovirus, Alphainfluenzavirus influenzae (H1N1, H2Nx, H3N2, H5Nx, H6Nx, H7Nx, H10Nx)], hemorrhagic fever viruses (Mammarenavirus lassaense, Orthoebolavirus zairense, Orthoebolavirus sudanense, Orthomarburgvirus marburgense, Orthohantavirus hantanense, Orthohantavirus sinnombreense, Orthonairovirus haemorrhagiae, Henipavirus nipahense), poxviruses (Orthopoxvirus variola, Orthopoxvirus monkeypox), insect-borne viruses (Orthoflavivirus flavi, Orthoflavivirus denguei, Orthoflavivirus zikaense, Bandavirus dabieense, Alphavirus chikungunya, Alphavirus venezuelan), Enterovirus coxsackiepol, and Lentivirus humimdef1. The bacteria in the Priority Pathogens List usually cause respiratory or intestinal symptoms, including Vibrio cholerae (O139), Yersinia pestis, Shigella dysenteriae serotype 1, Salmonella enterica non-typhoidal serovars, and Klebsiella pneumoniae, which cause cholera, plague, bacillary dysentery, gastroenteritis, and pneumonia. Some Priority Pathogens exhibit a global distribution, being present in all six WHO Regions (African Region, Region of the Americas, Eastern Mediterranean Region, European Region, South-East Asia Region, and Western Pacific Region), while others are concentrated in specific regions, often associated with the presence of animal reservoirs, transmission vectors, or poor living conditions. Pathogens with worldwide distribution encompass both viruses (such as Subgenus Sarbecovirus, Alphainfluenzavirus influenzae, Orthopoxvirus monkeypox, Lentivirus humimdef1, and Orthoflavivirus denguei) and bacteria (such as Salmonella enterica non-typhoidal serovars and Klebsiella pneumoniae). The distribution of these pathogens across diverse nations and regions underscores the important role of international collaboration. In addition, a “Family approach” is introduced, which instead of focusing on isolated known high-risk pathogens, extending research and preparation to the entire pathogen family [1]. This is the original intention behind the proposal of the concept of Priority Pathogens or their families. The Priority Pathogens include the viruses that belong to 13 virus families. The family that contains at least one Priority Pathogen is defined as a Priority Family, and their risk levels are evaluated. Eleven virus families and one group of bacteria are considered of high risk (Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, Hantaviridae, Nairoviridae, Orthomyxoviridae, Paramyxoviridae, Phenuiviridae, Poxviridae, Togaviridae, bacteria), two families of medium risk (Picornaviridae, Retroviridae), and two families are of low to medium risk (Adenoviridae, Pneumoviridae). The other fourteen families are considered of low risk (Anelloviridae, Astroviridae, Bornaviridae, Hepadnaviridae, Hepeviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Peribunyaviridae, Picobirnaviridae, Polyomaviridae, Rhabdoviridae, Sedoreoviridae, Spinareoviridae) for there are no Priority Pathogens in these virus families. As the pathogens in the same family share a large number of similarities, such as genomes, structures, transmission routes, infection & immune mechanisms and vaccine/drug targets, the research on family is likely to help to respond efficiently to unforeseen variants, emerging pathogens, and unknown threats [1]. Protective immunogens Protective immunogens are defined as the definite immunogen (s) of pathogens that play a protective role when administered to animals in challenge tests, such as an increased survival rate, reduced tissue damage or decreased viral titer, or a significant production of neutralizing antibodies. Protective immunogens of viruses are important candidates in the development of vaccines due to their ability of stimulating host immune responses. Protective immunogens also provide the targets for screening neutralizing antibodies and other drugs when an emerging pathogen spreads even if there are no proper vaccines. Representative protective immunogens of Priority Pathogens were searched and summarized in Table 1 [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93], [94], [95], [96], [97], [98], [99], [100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124]. For many viruses, protective immunogens are those surface components that mediate viral adsorption and entry into host cells (Fig. 1). Viruses within the same family usually share similar genomes, structures, transmission routes, and immune mechanisms, as well as protective immunogens which are located on homologous proteins or homologous sequences [125], [126]. For example, Zika virus, dengue virus, and other flaviviruses invade host cells through surface envelope (E) protein, and many of the key protective targets of the developed vaccines also come from E protein or part of it. The diverse protective immunogens on the surface of virus are usually the targets of neutralizing antibodies [127]. The relatively conservative nucleoproteins of viruses are usually the targets of cell immunity, which may act as universal vaccine targets (Fig. 1, Fig. 2).Table 1Protective immunogens for Priority Pathogens.FamilyPriority Pathogen (s)More familiar nameProtective immunogen (s) *aStrategyAnimals *bEfficacy *cReferenceArenaviridaeMammarenavirus lassaenseLassa virus (LASV)GPC #1[2], [3]mRNAGuinea pigs100% survival[4]NP #2[5], [6]MeV vectorCynomolgus macaques100% survival[7]BacteriaVibrio cholerae (O139)−LPS + cholera toxin BSubunitRabbitsSignificant protection (increased ED50)[8]Yersinia pestis−F1 capsule antigen #3[9], [10]mRNAC57BL/6JOlaHsd mice100% survival[11]LcrV #4[12], [13]Protein subunitBALB/c mice100% survival[14]YopEProtein subunitC57BL/6 mice83% survival[15]Shigella dysenteriae serotype 1Shigella dysenteria 1LPS O-antigenRecombinant strainsA/J mice100% survival[16]Ipa #5[17], [18]Protein subunitBALB/c mice100% survival[19]Salmonella enterica non typhoidal serovarsNon-typhoidal Salmonella entericaLPS O-antigen #6[20]Recombinant strainsBALB/c mice100% survival[21]Flagellin H-antigenProtein subunitCD-1 Mice100% survival[22]T3SS-1 SipDProtein subunitBALB/c mice71.5% survival[23]Klebsiella pneumoniae−Capsule polysaccharide (CPS)#7[24], [25]Subunit (a purified CPS)SD rats100% survival[26]Omp #8[27], [28], [29]Protein subunitBALB/c mice83% survival[30]CoronaviridaeSubgenus SarbecovirusSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Spike (S) protein #9[31], [32], [33]Protein subunithACE2-Tg mice and Rhesus macaquesSignificant reduction of viral load[34]Severe acute respiratory syndrome coronavirus (SARS-CoV)Spike (S) protein #10[31], [35], [36]VLPBALB/c mice100% survival[37]NPVRPs vectorBALB/c mice100% survival[38]CoronaviridaeSubgenus MerbecovirusMiddle East respiratory syndromecoronavirus (MERS-CoV)Spike (S) protein #11[31], [39], [40]Protein subunitBALB/c miceSignificant reduction of viral load[41]FiloviridaeOrthoebolavirus zairenseEbola virus (EBOV)Glycoprotein (GP) #12[42], [43], [44], [45]VSV vectorCynomolgus macaques100% survival[46]NPVEEV replicons vectorC57BL/6 mice80% survival[47]FiloviridaeOrthoebolavirus sudanenseSudan ebolavirus (SUDV)Glycoprotein (GP) #13[43], [48]VSVCynomolgus macaques100% survival[49]FiloviridaeOrthomarburgvirus marburgenseMarburg virus (MARV)Glycoprotein (GP) #14[43], [44], [50]cAd3 vectorCynomolgus macaques100% survival[51]NPAntisense nucleosidesCynomolgus macaques100% survival[52]FlaviviridaeOrthoflavivirus flaviYellow fever virus (YFV)Envelope (E) protein #15[53], [54]DNAC57Bl/6 and BALB/c mice100% survival[55]NS proteinProtein subunitRhesus macaquesMarked reduction viremia (80%)[56]FlaviviridaeOrthoflavivirus dengueiDengue virus (DENV)Envelope (E) protein #16[57], [58]DNABALB/c mice100% survival[59]NS protein#17[60]DNABALB/c mice90% survival[61]FlaviviridaeOrthoflavivirus zikaenseZika virus (ZIKV)Envelope (E) protein #18[62], [63], [64], [65]Protein subunitIfnar1−/− mice100% survival[66]NS protein #19[67], [68]MVA vectorOutbred CD-1/ICR mice100% survival[69]HantaviridaeOrthohantavirus hantanenseHantaan virus (HTNV)Gn/Gc #20[70], [71], [72]Protein subunitBALB/c mice100% survival[73]NP #21[70]Protein subunitHLA-A2.1/Kb Tg MiceSignificant reduction of viral load[74]HantaviridaeOrthohantavirus sinnombreenseSin Nombre virus (SNV)Gn/Gc or GPC #22[75], [76]rVSVΔG vectorSyrian hamsters83% survival[77]NPDNADeer mice80% protection against infection[78]NairoviridaeOrthonairovirus haemorrhagiaeCrimean-Congo hemorrhagic fever virus (CCHFV)Gn/Gc or GPC #23[79], [80]rVSV vectorSTAT-1 knock-out mice100% survival[81]NP #24[79], [82]Ad vectorIFNAR-/- mice78% survival[83]OrthomyxoviridaeAlphainfluenzavirus influenzae (H1N1, H2Nx, H3N2, H5Nx, H6Nx, H7Nx, H10Nx)Influenza A virus (IAV)Hemagglutinin (HA) #25[84], [85]Ad vectorBALB/cJ mice100% survival[86]Neuraminidase (NA)Mi3 self-assembling protein nanoparticlesBALB/c mice100% survival[87]Matrix (M) protein #26[88]Porcine circovirus type 2 (PCV2)Mice100% survival[89]ParamyxoviridaeHenipavirus nipahenseNipah virus (NiV)Attachment glycoprotein (G) #27[90], [91]rVSV vectorsFerrets100% survival[92]Fusion glycoprotein F0 (F) #28[93], [94]rVSV vectorsFerrets100% survival[92]PhenuiviridaeBandavirus dabieenseSevere fever with thrombocytopenia syndrome virus (SFTSV)Glycoprotein N (Gn) #29[95], [96]LNP-mRNAC57BL/6 mice100% survival[97]NPProtein subunitIFNAR-KO mice66.7% survival[98]PicornaviridaeEnterovirus coxsackiepolPoliovirus (PV)Capsid protein (D antigen)IPV (IPV heated to remove its D antigen did not induce protection)hPVR-Tg mice100% survival[99]PoxviridaeOrthopoxvirus variolaVariola virus (VARV)A30 + B7 + F8 #30Protein subunitBALB/c mice100% survival[100]VACV EEV (B5) #31[101], [102], [103]DNABALB/c mice100% survival[104]VACV EEV (A33) #32[104]Protein subunitBALB/c mice100% survival[101]VACV IMV (L1) #33DNAMice80% survival[105]VACV IMV (A27) #34[105], [106]DNABALB/c mice80% survival[104]VACV IMV + EEV (A33 + B5 + L1 + A27) #35DNABALB/c mice100% survival[107]PoxviridaeOrthopoxvirus monkeypoxMpox virus (MPXV)IMV (M1R)BoHV-4 vectorSTAT1 knockout mice100% survival[108]EEV + IMV (A35 + B6 + M1) #36[109], [110]mRNABALB/c micesignificant reduction of viral load[111]EEV + IMV (A35 + B6 + M1 + A29) #37[112], [113]mRNACynomolgus macaque100% survival[114]RetroviridaeLentivirus humimdef1Human immunodeficiency virus 1 (HIV-1) *dEnvelope glycoprotein (Env) [115]Protein subunitChimpanzees100% protection against acquisition of infection[116]Env + NS protein (Gag-Pol)Ad or poxvirus vectorRhesus macaques80% protection against acquisition of infection[117]Env + Gag-Pol-NefDNA or rAd vectorRhesus macaquesSignificant reduction of viral load[118]TogaviridaeAlphavirus chikungunyaChikungunya virus (CHIKV)Envelope glycoprotein #38[119], [120]DNABALB/c mice100% survival[121]TogaviridaeAlphavirus venezuelanVenezuelan equine encephalitis virus (VEEV)Envelope glycoprotein #39[122], [123]Protein subunitCD-1 mice100% survival[124]*aProtective immunogens are defined as certain immunogen (s) of pathogens that have a protective effect when administered to animals in challenge tests, such as increased survival rate, reduced viral titer. This table summarized studies validating the protective efficacy of candidate protective immunogens. Due to space limitations, only representative references were cited herein, with a more comprehensive list shown in Supplementary Table S1. *b The number of animals for challenge tests are dependent on the specific experimental design. In general, at least 5–6 rodents or 3 non-human primates per group are enough for statistical difference. Ethics is also a factor that needs to be taken into consideration. The detailed experimental parameters can be found in the original peer-reviewed references. *c Efficacy of protective immunogen are assessed by survival rate or significant reduction of viral load in lethal challenge tests. For some pathogens that are not fatal in a short time, such as HIV-1, protective efficacy is assessed by protection rates. *d HIV-1 vaccine is still not available.#1Attached are more reports on protective immunogen GPC or GPC + NP of Lassa virus; #2 Attached are more reports on protective immunogen NP of Lassa virus; #3 Attached are more reports on protective immunogen F1 capsule antigen or F1 + LcrV of Yersinia pestis; #4 Attached are more reports on protective LcrV or LcrV + YopE of Yersinia pestis; #5 Attached are more reports on protective Ipa of Shigella dysenteria 1; #6 Attached are more reports on protective LPS O-antigen + flagellin H-antigen of non-typhoidal Salmonella enterica; #7 Attached are more reports on protective CPS or CPS + Omp of Klebsiella pneumoniae; #8 Attached are more reports on protective Omp or other proteins of Klebsiella pneumoniae; #9 Attached are more reports on protective S protein (or only RBD) of SARS-CoV-2; #10 Attached are more reports on protective S protein (or only RBD) of SARS-CoV; #11 Attached are more reports on protective S protein (or RBD, S1, or VLP) of MERS-CoV; #12 Attached are more reports on protective GP or GP + NP of EBOV; #13 Attached are more reports on protective GP or GP + NP of SUDV; #14 Attached are more reports on protective GP of Marburg virus; #15 Attached are more reports on protective envelope or envelope + membrane protein of yellow fever virus; #16 Attached are more reports on protective envelope or envelope + membrane protein of dengue virus; #17 Attached are more reports on protective NS of dengue virus; #18 Attached are more reports on protective envelope or envelope + membrane protein or envelope + NS protein of Zika virus; #19 Attached are more reports on protective NS1 or protective immunogen containing NS1or NS3 of Zika virus; #20 Attached are more reports on protective envelope glycoprotein, including Gn and Gc, or GPC + NP of Hantaan virus; #21 Attached are more reports on protective NP of Hantaan virus; #22 Attached are more reports on protective GPC (GnGc) of Sin Nombre virus; #23 Attached are more reports on protective GPC (or GnGc) or GPC + NP of CCHFV; #24 Attached are more reports on protective NP or NP fused with lysosome-associated membrane protein 1 (LAMP1) of CCHFV; #25 Attached are more reports on protective HA or protective immunogen containing HA and other proteins of Influenza A virus; #26 Attached are more reports on protective M protein of Influenza A virus; #27 Attached are more reports on protective G protein or G + F protein of Nipah virus; #28 Attached are more reports on protective F protein of Nipah virus; #29 Attached are more reports on protective Gn/Gc protein of SFTS virus; Gn/Gc or Gn/Gc + NP were also protective immunogens in some references; #30 The animals were challenged with VACV virus; #31 Attached are more reports on protective B5 or B5 + L1 (or B5 + A27) protein of VACV virus; The animals were challenged with VACV; #32 Attached are more reports on protective A33 protein of VACV virus; The animals were challenged with VACV; #33 The animals were challenged with VACV; #34 Attached are more reports on protective A27 protein of VACV; The animals were challenged with VACV; #35 The animals were challenged with VACV; #36 Attached are more reports on protective A35 + B6 + M1 or A35 + B6 + M1 + H3 of mpox virus; #37 Attached are more reports on protective A35R + B6R + M1R + A29L or A35R + B6R + M1R + A29L + E8L or more combination of EEV and IMV of mpox virus; #38 Attached are more reports on protective envelope glycoprotein, envelope polyprotein (E3-E2-6K-E1) or structural polyprotein, for example, capsid and envelope structural proteins (C-E3-E2-6K-E1) of CHIKV; #39 Attached are more reports on protective envelope polyprotein (E3-E2-6K-E1) or structural protein (C-E3-E2-6K-E1) of VEEV.Abbreviations: GPC, glycoprotein complex (can be then processed into Gn and Gc); NP, nucleoprotein; LPS, lipopolysaccharide; MeV, Measles virus; LcrV, low calcium response V antigen; YopE, outer membrane virulence protein E; Ipa, invasion plasmid antigens; T3SS-1, type III secretion system 1; SipD, Salmonella invasion protein D; Omp, outer membrane protein; VLP, virus-like particle; VRP, Venezuelan equine encephalitis replicon particle; VSV, vesicular stomatitis virus; VEEV, Venezuelan equine encephalitis virus; cAd3, chimpanzee adenovirus type 3; NS, non-structural; MVA, Modified Vaccinia Ankara; Gn, glycoprotein N; Gc, glycoprotein C; rVSV, recombinant vesicular stomatitis virus; Ad, adenovirus; IPV, inactivated polio vaccine; hPVR-Tg mice, human poliovirus receptor transgenic mice; BoHV-4, recombinant bovine herpesvirus 4; EEV, extracellular enveloped virus; IMV, intracellular mature virus; rAd, recombinant adenovirus; mAb, monoclonal antibody; hACE2-Tg mice, human angiotensin-converting enzyme 2 transgenic mice; ED50, median effective dose.Fig. 1The protective immunogens of Priority Pathogens are located on the surface proteins or in the interior of virus. The viruses within the same family are aligned in the same row. A) Red indicates the protective immunogens on the virus surface, including GP, S protein, E protein, Gn/Gc, etc. B) Purple indicates the protective immunogens inside the virus, mainly NP. Abbreviations: GP, glycoprotein; S protein, spike protein; Gn, glycoprotein N; Gc, glycoprotein C; E protein, envelope protein; IMV, intracellular mature virus; EEV, extracellular enveloped virus; HA, hemagglutinin; NA, neuraminidase; F, fusion glycoprotein; G, attachment glycoprotein; Env, envelope glycoprotein; NP, nucleoprotein.Fig. 2The comparison of the protective immunogen of virus in the Priority Pathogens List. The name of the envelope protein on the surface of virus was a little different, such as envelope glycoprotein (Env) for Lentivirus humimdef1, envelope (E) protein for the virus in Flaviviridae, Togaviridae, and Coronaviridae. Abbreviations: GPC, glycoprotein complex; S protein, spike protein; GP, glycoprotein; Gn, glycoprotein N; Gc, glycoprotein C; HA, hemagglutinin; NA, neuraminidase; G, attachment glycoprotein; F, fusion glycoprotein; EEV, extracellular enveloped virus; IMV, intracellular mature virus; NP, nucleoprotein; NS protein, nonstructural protein. Table 1Protective immunogens for Priority Pathogens.FamilyPriority Pathogen (s)More familiar nameProtective immunogen (s) *aStrategyAnimals *bEfficacy *cReferenceArenaviridaeMammarenavirus lassaenseLassa virus (LASV)GPC #1[2], [3]mRNAGuinea pigs100% survival[4]NP #2[5], [6]MeV vectorCynomolgus macaques100% survival[7]BacteriaVibrio cholerae (O139)−LPS + cholera toxin BSubunitRabbitsSignificant protection (increased ED50)[8]Yersinia pestis−F1 capsule antigen #3[9], [10]mRNAC57BL/6JOlaHsd mice100% survival[11]LcrV #4[12], [13]Protein subunitBALB/c mice100% survival[14]YopEProtein subunitC57BL/6 mice83% survival[15]Shigella dysenteriae serotype 1Shigella dysenteria 1LPS O-antigenRecombinant strainsA/J mice100% survival[16]Ipa #5[17], [18]Protein subunitBALB/c mice100% survival[19]Salmonella enterica non typhoidal serovarsNon-typhoidal Salmonella entericaLPS O-antigen #6[20]Recombinant strainsBALB/c mice100% survival[21]Flagellin H-antigenProtein subunitCD-1 Mice100% survival[22]T3SS-1 SipDProtein subunitBALB/c mice71.5% survival[23]Klebsiella pneumoniae−Capsule polysaccharide (CPS)#7[24], [25]Subunit (a purified CPS)SD rats100% survival[26]Omp #8[27], [28], [29]Protein subunitBALB/c mice83% survival[30]CoronaviridaeSubgenus SarbecovirusSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Spike (S) protein #9[31], [32], [33]Protein subunithACE2-Tg mice and Rhesus macaquesSignificant reduction of viral load[34]Severe acute respiratory syndrome coronavirus (SARS-CoV)Spike (S) protein #10[31], [35], [36]VLPBALB/c mice100% survival[37]NPVRPs vectorBALB/c mice100% survival[38]CoronaviridaeSubgenus MerbecovirusMiddle East respiratory syndromecoronavirus (MERS-CoV)Spike (S) protein #11[31], [39], [40]Protein subunitBALB/c miceSignificant reduction of viral load[41]FiloviridaeOrthoebolavirus zairenseEbola virus (EBOV)Glycoprotein (GP) #12[42], [43], [44], [45]VSV vectorCynomolgus macaques100% survival[46]NPVEEV replicons vectorC57BL/6 mice80% survival[47]FiloviridaeOrthoebolavirus sudanenseSudan ebolavirus (SUDV)Glycoprotein (GP) #13[43], [48]VSVCynomolgus macaques100% survival[49]FiloviridaeOrthomarburgvirus marburgenseMarburg virus (MARV)Glycoprotein (GP) #14[43], [44], [50]cAd3 vectorCynomolgus macaques100% survival[51]NPAntisense nucleosidesCynomolgus macaques100% survival[52]FlaviviridaeOrthoflavivirus flaviYellow fever virus (YFV)Envelope (E) protein #15[53], [54]DNAC57Bl/6 and BALB/c mice100% survival[55]NS proteinProtein subunitRhesus macaquesMarked reduction viremia (80%)[56]FlaviviridaeOrthoflavivirus dengueiDengue virus (DENV)Envelope (E) protein #16[57], [58]DNABALB/c mice100% survival[59]NS protein#17[60]DNABALB/c mice90% survival[61]FlaviviridaeOrthoflavivirus zikaenseZika virus (ZIKV)Envelope (E) protein #18[62], [63], [64], [65]Protein subunitIfnar1−/− mice100% survival[66]NS protein #19[67], [68]MVA vectorOutbred CD-1/ICR mice100% survival[69]HantaviridaeOrthohantavirus hantanenseHantaan virus (HTNV)Gn/Gc #20[70], [71], [72]Protein subunitBALB/c mice100% survival[73]NP #21[70]Protein subunitHLA-A2.1/Kb Tg MiceSignificant reduction of viral load[74]HantaviridaeOrthohantavirus sinnombreenseSin Nombre virus (SNV)Gn/Gc or GPC #22[75], [76]rVSVΔG vectorSyrian hamsters83% survival[77]NPDNADeer mice80% protection against infection[78]NairoviridaeOrthonairovirus haemorrhagiaeCrimean-Congo hemorrhagic fever virus (CCHFV)Gn/Gc or GPC #23[79], [80]rVSV vectorSTAT-1 knock-out mice100% survival[81]NP #24[79], [82]Ad vectorIFNAR-/- mice78% survival[83]OrthomyxoviridaeAlphainfluenzavirus influenzae (H1N1, H2Nx, H3N2, H5Nx, H6Nx, H7Nx, H10Nx)Influenza A virus (IAV)Hemagglutinin (HA) #25[84], [85]Ad vectorBALB/cJ mice100% survival[86]Neuraminidase (NA)Mi3 self-assembling protein nanoparticlesBALB/c mice100% survival[87]Matrix (M) protein #26[88]Porcine circovirus type 2 (PCV2)Mice100% survival[89]ParamyxoviridaeHenipavirus nipahenseNipah virus (NiV)Attachment glycoprotein (G) #27[90], [91]rVSV vectorsFerrets100% survival[92]Fusion glycoprotein F0 (F) #28[93], [94]rVSV vectorsFerrets100% survival[92]PhenuiviridaeBandavirus dabieenseSevere fever with thrombocytopenia syndrome virus (SFTSV)Glycoprotein N (Gn) #29[95], [96]LNP-mRNAC57BL/6 mice100% survival[97]NPProtein subunitIFNAR-KO mice66.7% survival[98]PicornaviridaeEnterovirus coxsackiepolPoliovirus (PV)Capsid protein (D antigen)IPV (IPV heated to remove its D antigen did not induce protection)hPVR-Tg mice100% survival[99]PoxviridaeOrthopoxvirus variolaVariola virus (VARV)A30 + B7 + F8 #30Protein subunitBALB/c mice100% survival[100]VACV EEV (B5) #31[101], [102], [103]DNABALB/c mice100% survival[104]VACV EEV (A33) #32[104]Protein subunitBALB/c mice100% survival[101]VACV IMV (L1) #33DNAMice80% survival[105]VACV IMV (A27) #34[105], [106]DNABALB/c mice80% survival[104]VACV IMV + EEV (A33 + B5 + L1 + A27) #35DNABALB/c mice100% survival[107]PoxviridaeOrthopoxvirus monkeypoxMpox virus (MPXV)IMV (M1R)BoHV-4 vectorSTAT1 knockout mice100% survival[108]EEV + IMV (A35 + B6 + M1) #36[109], [110]mRNABALB/c micesignificant reduction of viral load[111]EEV + IMV (A35 + B6 + M1 + A29) #37[112], [113]mRNACynomolgus macaque100% survival[114]RetroviridaeLentivirus humimdef1Human immunodeficiency virus 1 (HIV-1) *dEnvelope glycoprotein (Env) [115]Protein subunitChimpanzees100% protection against acquisition of infection[116]Env + NS protein (Gag-Pol)Ad or poxvirus vectorRhesus macaques80% protection against acquisition of infection[117]Env + Gag-Pol-NefDNA or rAd vectorRhesus macaquesSignificant reduction of viral load[118]TogaviridaeAlphavirus chikungunyaChikungunya virus (CHIKV)Envelope glycoprotein #38[119], [120]DNABALB/c mice100% survival[121]TogaviridaeAlphavirus venezuelanVenezuelan equine encephalitis virus (VEEV)Envelope glycoprotein #39[122], [123]Protein subunitCD-1 mice100% survival[124]*aProtective immunogens are defined as certain immunogen (s) of pathogens that have a protective effect when administered to animals in challenge tests, such as increased survival rate, reduced viral titer. This table summarized studies validating the protective efficacy of candidate protective immunogens. Due to space limitations, only representative references were cited herein, with a more comprehensive list shown in Supplementary Table S1. *b The number of animals for challenge tests are dependent on the specific experimental design. In general, at least 5–6 rodents or 3 non-human primates per group are enough for statistical difference. Ethics is also a factor that needs to be taken into consideration. The detailed experimental parameters can be found in the original peer-reviewed references. *c Efficacy of protective immunogen are assessed by survival rate or significant reduction of viral load in lethal challenge tests. For some pathogens that are not fatal in a short time, such as HIV-1, protective efficacy is assessed by protection rates. *d HIV-1 vaccine is still not available.#1Attached are more reports on protective immunogen GPC or GPC + NP of Lassa virus; #2 Attached are more reports on protective immunogen NP of Lassa virus; #3 Attached are more reports on protective immunogen F1 capsule antigen or F1 + LcrV of Yersinia pestis; #4 Attached are more reports on protective LcrV or LcrV + YopE of Yersinia pestis; #5 Attached are more reports on protective Ipa of Shigella dysenteria 1; #6 Attached are more reports on protective LPS O-antigen + flagellin H-antigen of non-typhoidal Salmonella enterica; #7 Attached are more reports on protective CPS or CPS + Omp of Klebsiella pneumoniae; #8 Attached are more reports on protective Omp or other proteins of Klebsiella pneumoniae; #9 Attached are more reports on protective S protein (or only RBD) of SARS-CoV-2; #10 Attached are more reports on protective S protein (or only RBD) of SARS-CoV; #11 Attached are more reports on protective S protein (or RBD, S1, or VLP) of MERS-CoV; #12 Attached are more reports on protective GP or GP + NP of EBOV; #13 Attached are more reports on protective GP or GP + NP of SUDV; #14 Attached are more reports on protective GP of Marburg virus; #15 Attached are more reports on protective envelope or envelope + membrane protein of yellow fever virus; #16 Attached are more reports on protective envelope or envelope + membrane protein of dengue virus; #17 Attached are more reports on protective NS of dengue virus; #18 Attached are more reports on protective envelope or envelope + membrane protein or envelope + NS protein of Zika virus; #19 Attached are more reports on protective NS1 or protective immunogen containing NS1or NS3 of Zika virus; #20 Attached are more reports on protective envelope glycoprotein, including Gn and Gc, or GPC + NP of Hantaan virus; #21 Attached are more reports on protective NP of Hantaan virus; #22 Attached are more reports on protective GPC (GnGc) of Sin Nombre virus; #23 Attached are more reports on protective GPC (or GnGc) or GPC + NP of CCHFV; #24 Attached are more reports on protective NP or NP fused with lysosome-associated membrane protein 1 (LAMP1) of CCHFV; #25 Attached are more reports on protective HA or protective immunogen containing HA and other proteins of Influenza A virus; #26 Attached are more reports on protective M protein of Influenza A virus; #27 Attached are more reports on protective G protein or G + F protein of Nipah virus; #28 Attached are more reports on protective F protein of Nipah virus; #29 Attached are more reports on protective Gn/Gc protein of SFTS virus; Gn/Gc or Gn/Gc + NP were also protective immunogens in some references; #30 The animals were challenged with VACV virus; #31 Attached are more reports on protective B5 or B5 + L1 (or B5 + A27) protein of VACV virus; The animals were challenged with VACV; #32 Attached are more reports on protective A33 protein of VACV virus; The animals were challenged with VACV; #33 The animals were challenged with VACV; #34 Attached are more reports on protective A27 protein of VACV; The animals were challenged with VACV; #35 The animals were challenged with VACV; #36 Attached are more reports on protective A35 + B6 + M1 or A35 + B6 + M1 + H3 of mpox virus; #37 Attached are more reports on protective A35R + B6R + M1R + A29L or A35R + B6R + M1R + A29L + E8L or more combination of EEV and IMV of mpox virus; #38 Attached are more reports on protective envelope glycoprotein, envelope polyprotein (E3-E2-6K-E1) or structural polyprotein, for example, capsid and envelope structural proteins (C-E3-E2-6K-E1) of CHIKV; #39 Attached are more reports on protective envelope polyprotein (E3-E2-6K-E1) or structural protein (C-E3-E2-6K-E1) of VEEV.Abbreviations: GPC, glycoprotein complex (can be then processed into Gn and Gc); NP, nucleoprotein; LPS, lipopolysaccharide; MeV, Measles virus; LcrV, low calcium response V antigen; YopE, outer membrane virulence protein E; Ipa, invasion plasmid antigens; T3SS-1, type III secretion system 1; SipD, Salmonella invasion protein D; Omp, outer membrane protein; VLP, virus-like particle; VRP, Venezuelan equine encephalitis replicon particle; VSV, vesicular stomatitis virus; VEEV, Venezuelan equine encephalitis virus; cAd3, chimpanzee adenovirus type 3; NS, non-structural; MVA, Modified Vaccinia Ankara; Gn, glycoprotein N; Gc, glycoprotein C; rVSV, recombinant vesicular stomatitis virus; Ad, adenovirus; IPV, inactivated polio vaccine; hPVR-Tg mice, human poliovirus receptor transgenic mice; BoHV-4, recombinant bovine herpesvirus 4; EEV, extracellular enveloped virus; IMV, intracellular mature virus; rAd, recombinant adenovirus; mAb, monoclonal antibody; hACE2-Tg mice, human angiotensin-converting enzyme 2 transgenic mice; ED50, median effective dose. Protective immunogens for Priority Pathogens. Protective immunogens are defined as certain immunogen (s) of pathogens that have a protective effect when administered to animals in challenge tests, such as increased survival rate, reduced viral titer. This table summarized studies validating the protective efficacy of candidate protective immunogens. Due to space limitations, only representative references were cited herein, with a more comprehensive list shown in Supplementary Table S1. *b The number of animals for challenge tests are dependent on the specific experimental design. In general, at least 5–6 rodents or 3 non-human primates per group are enough for statistical difference. Ethics is also a factor that needs to be taken into consideration. The detailed experimental parameters can be found in the original peer-reviewed references. *c Efficacy of protective immunogen are assessed by survival rate or significant reduction of viral load in lethal challenge tests. For some pathogens that are not fatal in a short time, such as HIV-1, protective efficacy is assessed by protection rates. *d HIV-1 vaccine is still not available. Attached are more reports on protective immunogen GPC or GPC + NP of Lassa virus; #2 Attached are more reports on protective immunogen NP of Lassa virus; #3 Attached are more reports on protective immunogen F1 capsule antigen or F1 + LcrV of Yersinia pestis; #4 Attached are more reports on protective LcrV or LcrV + YopE of Yersinia pestis; #5 Attached are more reports on protective Ipa of Shigella dysenteria 1; #6 Attached are more reports on protective LPS O-antigen + flagellin H-antigen of non-typhoidal Salmonella enterica; #7 Attached are more reports on protective CPS or CPS + Omp of Klebsiella pneumoniae; #8 Attached are more reports on protective Omp or other proteins of Klebsiella pneumoniae; #9 Attached are more reports on protective S protein (or only RBD) of SARS-CoV-2; #10 Attached are more reports on protective S protein (or only RBD) of SARS-CoV; #11 Attached are more reports on protective S protein (or RBD, S1, or VLP) of MERS-CoV; #12 Attached are more reports on protective GP or GP + NP of EBOV; #13 Attached are more reports on protective GP or GP + NP of SUDV; #14 Attached are more reports on protective GP of Marburg virus; #15 Attached are more reports on protective envelope or envelope + membrane protein of yellow fever virus; #16 Attached are more reports on protective envelope or envelope + membrane protein of dengue virus; #17 Attached are more reports on protective NS of dengue virus; #18 Attached are more reports on protective envelope or envelope + membrane protein or envelope + NS protein of Zika virus; #19 Attached are more reports on protective NS1 or protective immunogen containing NS1or NS3 of Zika virus; #20 Attached are more reports on protective envelope glycoprotein, including Gn and Gc, or GPC + NP of Hantaan virus; #21 Attached are more reports on protective NP of Hantaan virus; #22 Attached are more reports on protective GPC (GnGc) of Sin Nombre virus; #23 Attached are more reports on protective GPC (or GnGc) or GPC + NP of CCHFV; #24 Attached are more reports on protective NP or NP fused with lysosome-associated membrane protein 1 (LAMP1) of CCHFV; #25 Attached are more reports on protective HA or protective immunogen containing HA and other proteins of Influenza A virus; #26 Attached are more reports on protective M protein of Influenza A virus; #27 Attached are more reports on protective G protein or G + F protein of Nipah virus; #28 Attached are more reports on protective F protein of Nipah virus; #29 Attached are more reports on protective Gn/Gc protein of SFTS virus; Gn/Gc or Gn/Gc + NP were also protective immunogens in some references; #30 The animals were challenged with VACV virus; #31 Attached are more reports on protective B5 or B5 + L1 (or B5 + A27) protein of VACV virus; The animals were challenged with VACV; #32 Attached are more reports on protective A33 protein of VACV virus; The animals were challenged with VACV; #33 The animals were challenged with VACV; #34 Attached are more reports on protective A27 protein of VACV; The animals were challenged with VACV; #35 The animals were challenged with VACV; #36 Attached are more reports on protective A35 + B6 + M1 or A35 + B6 + M1 + H3 of mpox virus; #37 Attached are more reports on protective A35R + B6R + M1R + A29L or A35R + B6R + M1R + A29L + E8L or more combination of EEV and IMV of mpox virus; #38 Attached are more reports on protective envelope glycoprotein, envelope polyprotein (E3-E2-6K-E1) or structural polyprotein, for example, capsid and envelope structural proteins (C-E3-E2-6K-E1) of CHIKV; #39 Attached are more reports on protective envelope polyprotein (E3-E2-6K-E1) or structural protein (C-E3-E2-6K-E1) of VEEV. Abbreviations: GPC, glycoprotein complex (can be then processed into Gn and Gc); NP, nucleoprotein; LPS, lipopolysaccharide; MeV, Measles virus; LcrV, low calcium response V antigen; YopE, outer membrane virulence protein E; Ipa, invasion plasmid antigens; T3SS-1, type III secretion system 1; SipD, Salmonella invasion protein D; Omp, outer membrane protein; VLP, virus-like particle; VRP, Venezuelan equine encephalitis replicon particle; VSV, vesicular stomatitis virus; VEEV, Venezuelan equine encephalitis virus; cAd3, chimpanzee adenovirus type 3; NS, non-structural; MVA, Modified Vaccinia Ankara; Gn, glycoprotein N; Gc, glycoprotein C; rVSV, recombinant vesicular stomatitis virus; Ad, adenovirus; IPV, inactivated polio vaccine; hPVR-Tg mice, human poliovirus receptor transgenic mice; BoHV-4, recombinant bovine herpesvirus 4; EEV, extracellular enveloped virus; IMV, intracellular mature virus; rAd, recombinant adenovirus; mAb, monoclonal antibody; hACE2-Tg mice, human angiotensin-converting enzyme 2 transgenic mice; ED50, median effective dose. The protective immunogens of Priority Pathogens are located on the surface proteins or in the interior of virus. The viruses within the same family are aligned in the same row. A) Red indicates the protective immunogens on the virus surface, including GP, S protein, E protein, Gn/Gc, etc. B) Purple indicates the protective immunogens inside the virus, mainly NP. Abbreviations: GP, glycoprotein; S protein, spike protein; Gn, glycoprotein N; Gc, glycoprotein C; E protein, envelope protein; IMV, intracellular mature virus; EEV, extracellular enveloped virus; HA, hemagglutinin; NA, neuraminidase; F, fusion glycoprotein; G, attachment glycoprotein; Env, envelope glycoprotein; NP, nucleoprotein. The comparison of the protective immunogen of virus in the Priority Pathogens List. The name of the envelope protein on the surface of virus was a little different, such as envelope glycoprotein (Env) for Lentivirus humimdef1, envelope (E) protein for the virus in Flaviviridae, Togaviridae, and Coronaviridae. Abbreviations: GPC, glycoprotein complex; S protein, spike protein; GP, glycoprotein; Gn, glycoprotein N; Gc, glycoprotein C; HA, hemagglutinin; NA, neuraminidase; G, attachment glycoprotein; F, fusion glycoprotein; EEV, extracellular enveloped virus; IMV, intracellular mature virus; NP, nucleoprotein; NS protein, nonstructural protein. In addition, different viruses may have cross-reactive protective immunogens, which may be more common in viruses within the same family. Historically, humans have been inoculated with vaccinia virus components against infection by variola virus, a virus from the same family [128]. Mpox vaccine protected animals from lethal challenge of vaccinia virus, and the individuals with smallpox vaccine (vaccinia virus) had the antibodies and T cells against mpox [110], [129], [130]. This suggests that cross-reactive protective immunogens may provide partially pre-stored immunity, which probably helps protect against infection by other viruses in the same family. The application of protective immunogens Although envelope proteins serve as dominant protective immunogens, their sequence divergence often limits cross-protective immunity among different viral species or strains. For instance, recombinant vesicular stomatitis virus (rVSV)-Zaire Ebola virus (EBOV) vaccine expresses Zaire Glycoprotein (GP), inducing the production of neutralizing antibodies and providing excellent protection for Zaire EBOV, but it shows almost no cross-neutralizing activity against Sudan GP [131]. Therefore, identifying conserved regions and epitopes to all Ebola virus GPs may provide insights for the development of universal vaccines. Another major challenge for RNA virus vaccine is the immune escape mutations arising from rapid virus evolution (Fig. 3). Immune escape hotspots are usually located on the protein surface regions that are easily accessible to and bound by antibodies. Therefore, timely and accurate surveillance of these viral variants is essential to evaluate their impacts on immunogenicity. With the development of advanced rapid pathogen detection and real-time transmission tracking techniques, researchers are using a combination of miniaturized molecular tools and high-throughput sequencing platforms, which enables timely update of vaccine antigens to match circulating variants [132]. On the other hand, improving antigen design for better vaccine or antibody performance requires moving beyond traditional approaches toward structure-based and rational immunogen engineering. One strategy is to target evolutionarily conserved epitopes, such as the stalk domain and the receptor-binding site footprint (e.g., Y98, W153) of influenza hemagglutinin (HA), to elicit broad protection [133], [134], [135], [136]. Another strategy is to modify glycosylation patterns through glycan masking to shield variable epitopes or glycan removal to expose conserved antigenic sites.Fig. 3The HA mutation sites analysis and evolution of seven representative H5 strains isolated from clinical samples. The HA0 amino acid sequence of A/VietNam/1194/2004 serves as the reference sequence, as shown in the grey background. The black dots represent those that are identical to the reference sequence, and the orange-highlighted indicate the mutation sites of amino acid compared to the reference sequence. The phylogenetic tree showing the evolution relationships among representative H5 strains was constructed using maximum likelihood method based on the amino acid sequence of the H5 HA protein. Abbreviation: HA, hemagglutinin. The HA mutation sites analysis and evolution of seven representative H5 strains isolated from clinical samples. The HA0 amino acid sequence of A/VietNam/1194/2004 serves as the reference sequence, as shown in the grey background. The black dots represent those that are identical to the reference sequence, and the orange-highlighted indicate the mutation sites of amino acid compared to the reference sequence. The phylogenetic tree showing the evolution relationships among representative H5 strains was constructed using maximum likelihood method based on the amino acid sequence of the H5 HA protein. Abbreviation: HA, hemagglutinin. The application of protective immunogens in bacterial vaccine development is more challenging than in viral vaccines. The extensive serotype diversity of bacteria, which is closely linked to virulence and epidemic potential, poses a major obstacle to the development of universal vaccines. For instance, Klebsiella pneumoniae has over 90 capsular (K) types, among which K1, K2, K5, and K20 are the most virulent [137]. A Klebsiella vaccine based on capsular K-antigens would lack the flexibility to adapt to changes in circulating strains. An alternative strategy is to target relatively conserved immunogens, such as outer membrane proteins or other receptor proteins [138]. However, the immunogenicity of these conserved antigens is often relatively weak. Lipopolysaccharide (LPS) represents a potentially ideal target due to its strong immunogenicity, but its inherent toxicity limits its use in subunit vaccines. To overcome this, the toxic lipid A portion can be removed while retaining the immunogenic O-antigen, or the O-antigen polysaccharide can be conjugated to a carrier protein to create a polysaccharide conjugate vaccine [139]. Nevertheless, due to the high diversity of O-antigens (e.g., Vibrio cholerae O139 vs. O1), the development of a truly universal bacterial vaccine remains a significant challenge. Beyond the optimization of target immunogens themselves, the selection of vaccine delivery platforms also directly determines the final performance and accessibility of vaccines. Messenger ribonucleic acid–lipid nanoparticle (mRNA-LNP) gives rapid reformulation to address viral immune escape variants but requires a cold chain. Vesicular stomatitis virus (VSV) vectors are thermostable but may be hindered by pre-existing immunity in the population. Ferritin nanoparticles boost the breadth of immune responses against diverse viral strains, but increase Chemistry, Manufacturing, and Controls (CMC) complexity. Protein subunit vaccines possess good consistency but adjuvants are normally required to enhance the immunogenicity of conserved antigens. The advantages and limitations of different new-type vaccine platforms should be taken into consideration. Protective immunogens identified in animal experiments have provided key clues for the development of drugs and vaccines. For example, Ebola GP vaccines listed in Table 1 (rVSV-EBOV) has already achieved 97.5% efficacy in humans, strongly supporting the translational value of preclinical animal data [140]. However, opportunities and challenges coexist. A protective immunogen validated in animals is far from being a “plug-and-play” vaccine product. For many viral envelope glycoproteins, maintaining their natural conformation is crucial for stimulating immune responses and eliciting neutralizing antibodies. It is a huge challenge to produce structurally correct and stable antigens on a large scale in the absence of the viral membrane. Protein glycosylation can greatly influence the immunogenicity, stability, and safety of antigens [141]. Glycosylation patterns may differ markedly between laboratory-scale transient transfection and large-scale Good Manufacturing Practice (GMP) continuous cell culture, potentially limiting the extrapolation of preclinical data. For many emerging and re-emerging infectious diseases, it is often unclear which immune responses (e.g., specific antibody titers or T-cell responses) can reliably predict protection in humans. Furthermore, some infectious diseases emerge suddenly in confined areas with uncertain case numbers, making it difficult to conduct large-scale Phase III trials. This uncertainty, in turn, reduces funding incentives and market drive. In summary, a validated antigen represents only the first step in the long journey of vaccine development (Fig. 4). Scalability, potency assays, manufacturing, and clinical translation are subsequent and often more arduous, costly stages.Fig. 4The list of proposed pre-clinical research for new vaccine development. Abbreviations: GMP, Good Manufacturing Practice; mAb, monoclonal antibody. The list of proposed pre-clinical research for new vaccine development. Abbreviations: GMP, Good Manufacturing Practice; mAb, monoclonal antibody. Prototype Pathogens and Pathogen X Meanwhile, the concept of Prototype Pathogens, representative pathogens from families with PHEIC or pandemic potential, has been created [1]. Prototype Pathogens can act as model species for basic-science studies and the development of therapies and vaccines. As many Priority Pathogens are limited to particular geographic regions, more than one Prototype Pathogen is selected for some virus families. However, Prototype Pathogens were not recommended for bacteria, because of the uniqueness of each priority bacteria [1]. Fifteen pathogens are both on the List of Priority Pathogens and Prototype Pathogens and encompass all families of high PHEIC risk Pathogens, indicating they are deserving of special attention for importance and representation. They are all emerging or re-emerging viruses causing public concerns, including Mammarenavirus lassaense, Subgenus Sarbecovirus, Subgenus Merbecovirus, Orthoebolavirus zairense, Orthoflavivirus denguei, Orthoflavivirus zikaense, Orthohantavirus sinnombreense, Orthonairovirus haemorrhagiae, Alphainfluenzavirus influenzae (H1N1, H5Nx), Henipavirus nipahense, Bandavirus dabieense, Orthopoxvirus monkeypox, Lentivirus humimdef1, Alphavirus chikungunya, and Alphavirus Venezuelan. Priority Pathogens are the key focus of attention for Pathogen X. Pathogen X denotes an unidentified or unspecified pathogen with the potential to induce significant outbreaks, PHEICs, or pandemics in the future [1]. Pathogen X is envisioned as an unidentified future hazard that could originate from recognized viruses within each viral family or potentially from viruses that are currently unidentified. Furthermore, potential alterations in the pathogen’s biology, patterns of transmission, and/or virulence could enable any pathogen to evolve into the next Pathogen X. Of particular significance is monitoring these changes and related factors which may cause these changes, such as climate, urbanization, and international travel. Pathogen X is very likely to come from a Priority Pathogen or a Priority Family. Therefore, potential Pathogen X is selected for each pathogen family, addressing the spectrum diversity of potential threats and the necessity of preparation in advance [1]. Some pathogens from the list may never cause an epidemic, and the one never thought of may be important in the future. To some extent, the priority of Pathogen X may depend on the genomic surveillance metrics, such as hotspot mutation, zoonotic pool, receptor compatibility, and codon usage. In 2024, the mpox epidemic spread rapidly in the Democratic Republic of the Congo and many places in Africa. On August 14, 2024, the mpox outbreak was again declared as a PHEIC [142]. This is the second time mpox has posed a global health threat after the PHEIC was first announced on July 23, 2022. Mpox is the second virus, after Ebola, to cause two PHEIC global outbreaks. The mpox virus belongs to the Orthopoxvirus family. In the same family, the smallpox virus is also a Priority Pathogen, and cowpox is assessed as Pathogen X. After the WHO declared smallpox eradicated in 1980, the population was no longer vaccinated, and newborn population had no immunity to the virus. Influenza A is one of the most rapidly mutating viruses. Two influenza A virus subtypes, H1N1 and H3N2, are currently circulating among people. In addition, influenza A viruses can infect many animals, including but not limited to wild birds, poultry, pigs, and cows, etc. It is uncommon for people to get influenza virus infections directly from animals. However, sporadic human infections and outbreaks caused by certain avian influenza A viruses have been reported. Five subtypes of avian influenza A viruses are known to have caused human infections (H5, H6, H7, H9, and H10 viruses) [143]. In 2024 and 2025, outbreaks of H5N1 in dairy cows were reported in multiple states of the US, and about 70 people who had exposure to these infected dairy cows were confirmed H5N1 infection, denoting likely mammal-to-human spread of H5N1 virus [144]. Several subtypes of influenza A viruses were listed as Priority Pathogens for high virulence. H9, with relatively weak virulence, is considered a Pathogen X. Perspectives In all, the updated Priority Pathogens List, as well as the recommendation of Prototype Pathogens for multiple virus families, provides new insights for future investigation of infectious pathogens. The research for Prototype Pathogens will expand our knowledge and understanding of other pathogens in the same family and build confidence when facing less-studied pathogen outbreaks. Currently, emerging and re-emerging infectious pathogens pose many challenges to humanity. Vaccines are important weapons in the fight against viruses, but vaccines for some important Priority Pathogens have not yet been successfully developed (Table 2). For example, there is still a lack of effective vaccines to prevent human immunodeficiency virus (HIV) infection. For other pathogens, such as influenza, although effective vaccines have been developed, the protective efficacy of vaccination may last for several months, and the virus mutates rapidly. Accordingly, vaccines need to be continuously optimized. Therefore, studies on the evolution and variation of viruses should still be strengthened. In the winter, there’s an alternate epidemic of multiple respiratory viruses, and co-infection is a common phenomenon. Developing a universal or multivalent vaccine may be a better option.Table 2Research progress of protective immunogens for Priority Pathogens.Priority PathogenResearch progress of protective immunogensCurrently available measuresProtective immunogenReproducibility across labsProtection in ≥ 2 speciesCorrelate of immunity definedHave entered clinical trialsDrugs or AbsVaccinesMammarenavirus lassaenseGPC√√√√××NP√√√×××Vibrio cholerae (O139)LPS + ctxB××××√√Yersinia pestisF1 capsule antigen√√√√√√LcrV√×√×√√YopE××√×√√Shigella dysenteriae serotype 1LPS O-antigen××√×√×Ipa√×√×√×Salmonella enterica non typhoidal serovarsLPS O-antigen√×√×√×flagellin H-antigen××√×√×T3SS-1 SipD××√×√×Klebsiella pneumoniaeCPS√√√×√×Omp√√√×√×Subgenus SarbecovirusS protein√√√√√√NP××√×√√Subgenus MerbecovirusS protein√√√√××Orthoebolavirus zairenseGP√√√√√√NP××√×√√Orthoebolavirus sudanenseGP√√√√××Orthomarburgvirus marburgenseGP√√√√××NP××√×××Orthoflavivirus flaviE protein√√√××√NS protein××√××√Orthoflavivirus dengueiE protein√√√××√NS protein√×√××√Orthoflavivirus zikaenseE protein√√√√××NS protein√×√×××Orthohantavirus hantanenseGn/Gc or GPC√√√××√NP√×√××√Orthohantavirus sinnombreenseGn/Gc or GPC√√√×××NP××××××Orthonairovirus haemorrhagiaeGn/Gc or GPC√√√×××NP√√√×××Alphainfluenzavirus influenzaeHA√√√√√√NA××√×√√M protein√×√×√×Henipavirus nipahenseG√√√√××F√√√×××Bandavirus dabieenseGn/Gc or GPC√√√×××NP××√×××Enterovirus coxsackiepolcapsid protein××√××√Orthopoxvirus variolaA30 + B7 + F8××√√×√VACV EEV√√√××√VACV IMV√×√××√VACV IMV + EEV××√××√Orthopoxvirus monkeypoxIMV××√××√EEV + IMV√√√××√Lentivirus humimdef1Env√√√√√×Alphavirus chikungunyaE protein√√√√×√Alphavirus venezuelanE protein√√√√××Ticks indicate Yes and crosses indicate Not Yet. Abbreviations: GPC, glycoprotein complex; NP, nucleoprotein; LPS, lipopolysaccharide; ctxB, cholera toxin B; LcrV, low calcium response V antigen; YopE, outer membrane virulence protein E; IPA, invasion plasmid antigens; T3SS-1, type III secretion system 1; SipD, Salmonella invasion protein D; CPS, capsule polysaccharide; Omp, outer membrane protein; S protein, spike protein; GP, glycoprotein; E protein, envelope protein; NS protein, nonstructural protein; Gn, glycoprotein N; Gc, glycoprotein C; HA, hemagglutinin; NA, neuraminidase; M protein, matrix protein; G, attachment glycoprotein; F, fusion glycoprotein; VACV, vaccinia virus; IMV, intracellular mature virus; EEV, extracellular enveloped virus; Env, envelope glycoprotein. Table 2Research progress of protective immunogens for Priority Pathogens.Priority PathogenResearch progress of protective immunogensCurrently available measuresProtective immunogenReproducibility across labsProtection in ≥ 2 speciesCorrelate of immunity definedHave entered clinical trialsDrugs or AbsVaccinesMammarenavirus lassaenseGPC√√√√××NP√√√×××Vibrio cholerae (O139)LPS + ctxB××××√√Yersinia pestisF1 capsule antigen√√√√√√LcrV√×√×√√YopE××√×√√Shigella dysenteriae serotype 1LPS O-antigen××√×√×Ipa√×√×√×Salmonella enterica non typhoidal serovarsLPS O-antigen√×√×√×flagellin H-antigen××√×√×T3SS-1 SipD××√×√×Klebsiella pneumoniaeCPS√√√×√×Omp√√√×√×Subgenus SarbecovirusS protein√√√√√√NP××√×√√Subgenus MerbecovirusS protein√√√√××Orthoebolavirus zairenseGP√√√√√√NP××√×√√Orthoebolavirus sudanenseGP√√√√××Orthomarburgvirus marburgenseGP√√√√××NP××√×××Orthoflavivirus flaviE protein√√√××√NS protein××√××√Orthoflavivirus dengueiE protein√√√××√NS protein√×√××√Orthoflavivirus zikaenseE protein√√√√××NS protein√×√×××Orthohantavirus hantanenseGn/Gc or GPC√√√××√NP√×√××√Orthohantavirus sinnombreenseGn/Gc or GPC√√√×××NP××××××Orthonairovirus haemorrhagiaeGn/Gc or GPC√√√×××NP√√√×××Alphainfluenzavirus influenzaeHA√√√√√√NA××√×√√M protein√×√×√×Henipavirus nipahenseG√√√√××F√√√×××Bandavirus dabieenseGn/Gc or GPC√√√×××NP××√×××Enterovirus coxsackiepolcapsid protein××√××√Orthopoxvirus variolaA30 + B7 + F8××√√×√VACV EEV√√√××√VACV IMV√×√××√VACV IMV + EEV××√××√Orthopoxvirus monkeypoxIMV××√××√EEV + IMV√√√××√Lentivirus humimdef1Env√√√√√×Alphavirus chikungunyaE protein√√√√×√Alphavirus venezuelanE protein√√√√××Ticks indicate Yes and crosses indicate Not Yet. Abbreviations: GPC, glycoprotein complex; NP, nucleoprotein; LPS, lipopolysaccharide; ctxB, cholera toxin B; LcrV, low calcium response V antigen; YopE, outer membrane virulence protein E; IPA, invasion plasmid antigens; T3SS-1, type III secretion system 1; SipD, Salmonella invasion protein D; CPS, capsule polysaccharide; Omp, outer membrane protein; S protein, spike protein; GP, glycoprotein; E protein, envelope protein; NS protein, nonstructural protein; Gn, glycoprotein N; Gc, glycoprotein C; HA, hemagglutinin; NA, neuraminidase; M protein, matrix protein; G, attachment glycoprotein; F, fusion glycoprotein; VACV, vaccinia virus; IMV, intracellular mature virus; EEV, extracellular enveloped virus; Env, envelope glycoprotein. Research progress of protective immunogens for Priority Pathogens. Ticks indicate Yes and crosses indicate Not Yet. Abbreviations: GPC, glycoprotein complex; NP, nucleoprotein; LPS, lipopolysaccharide; ctxB, cholera toxin B; LcrV, low calcium response V antigen; YopE, outer membrane virulence protein E; IPA, invasion plasmid antigens; T3SS-1, type III secretion system 1; SipD, Salmonella invasion protein D; CPS, capsule polysaccharide; Omp, outer membrane protein; S protein, spike protein; GP, glycoprotein; E protein, envelope protein; NS protein, nonstructural protein; Gn, glycoprotein N; Gc, glycoprotein C; HA, hemagglutinin; NA, neuraminidase; M protein, matrix protein; G, attachment glycoprotein; F, fusion glycoprotein; VACV, vaccinia virus; IMV, intracellular mature virus; EEV, extracellular enveloped virus; Env, envelope glycoprotein. The protective immunogen can be applied to the research and development of new vaccines such as protein vaccines, subunit vaccines, nucleic acid vaccines and virus-vector vaccines. With the development of vaccine research and development technology, new-type vaccines have been widely used in the prevention of infectious diseases. Furthermore, the development of neutralizing antibodies targeting these protective immunogens is also the preferred primary strategy for the development of antiviral drugs when a new pathogen emerges. Therefore, the screening of protective immunogens is particularly critical in the preparedness for the Priority Pathogens. Herein, we summarized the protective immunogens in different Priority Pathogens based on the current studies focusing on the vaccine or neutralizing antibody development (Table 1 and Fig. 2). For the enveloped viruses in the Priority Pathogens, the protective immunogens are mostly the envelope proteins which act as the viral receptor binding proteins. For instance, spike (S) protein in Coronaviridae such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, or glycoprotein in Filoviridae such as Ebola virus (EBOV), have been proven as key protective immunogens for vaccine and neutralizing antibody development. Furthermore, internal gene-expressed proteins, i.e., matrix (M) protein in influenza virus, or nucleoprotein (NP) in Hantaan virus and Ebola virus, are also important protective immunogens for vaccine development. Considering the high conservation of these proteins, which can also induce cross-reactive T cell responses, they are ideal targets for the universal vaccine development of the Priority Pathogens. Thus, the knowledge of the protective immunogens can provide pivotal information for the vaccine and drug preparation for the potential epidemic or pandemic of the Priority Pathogens. The studies around the protective immunogens would be the first key for combating the Priority Pathogens. It's essential to perform proactive pathogen surveillance and targeted basic research. The active surveillance of important pathogens or Priority Pathogens should be strengthened, including establishing a scientific monitoring network and a big database, as well as automatic analysis, evaluation, and even early warning. Based on the One Health approach, it is of importance to collect information on pathogens and mutations from various routes, including wild animals monitoring and environment monitoring such as wastewater [145]. In addition, the application of advanced technology such as artificial intelligence may assist the analysis of pathogen sequences and the study of mutation mechanisms, and it is likely to realize the prediction of new pathogen mutations in the future [146]. In all, a broader range of approaches, tools, and countermeasures should be adopted to adapt to emerging pandemic disease threats.